Alpelisib
from OncoPharm Hosted by John Bossaer
Discussing the 1st PI3-kinase inhibitor approved for a solid tumor, alpelisib for HR(+), HER2(-) metastatic breast cancer as 2nd line treatment. Worth sharing with her endocrine/DM colleagues...
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 20 minutes long.
When was this OncoPharm episode published?
This episode was published on May 30, 2019.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.